ELDA analysis demonstrated that the knockdown of FXYD3 remarkably decreased the spheroid-forming ability in vitro and tumor-initiating ability in vivo (Figure 4, A and B), providing strong evidence to support the notion that FXYD3 plays a crucial role in CSCs. The gene discussed is FXYD3; the disease is neoplasm.